AbCellera Biologics
ABCL
12.83
-0.32
-2.43%
AbCellera Biologics
US · ABCL
#2215 by market cap
Listed 2020
12.83
-0.32
-2.43%
Live - 5344 symbols - heartbeat 180s ago
· 2026-10-08 07:00
Pre-market
12.70
-1.01%
After-hours
12.85
+0.16%
Overnight
12.81
-0.16%
- Market cap
- 4.16B
- P/E (TTM)i
- -23.76
- P/Bi
- 4.64
- EPSi
- -0.49
- Div yieldi
- 0.00%
- 52W posi
- 82%
Reader sentiment
Are you bullish or bearish on ABCL?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 9 analysts
Buy
Avg price target
16.63 +29.6%
Price target rangecurrent 12.83
Low9.00
Avg16.63
High30.00
Buy 89%
Hold 11%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-29 | J.P. Morgan | -- | BUY | 17.00 |
| 2026-09-27 | JonesTrading | -- | BUY | 25.00 |
| 2026-09-24 | Goldman Sachs | -- | HOLD | 13.00 |
| 2026-09-02 | Truist Financial | -- | BUY | 30.00 |
| 2026-08-17 | BMO Capital | -- | BUY | 15.00 |
| 2026-08-11 | Truist Financial | -- | BUY | 30.00 |
| 2026-08-10 | JonesTrading | -- | BUY | 25.00 |
| 2026-08-10 | Truist Financial | -- | BUY | -- |
| 2026-08-10 | BMO Capital | -- | BUY | 15.00 |
| 2026-08-07 | Piper Sandler | -- | BUY | 12.00 |
| 2026-08-06 | Stifel | -- | BUY | 9.00 |
| 2026-08-05 | TD Cowen | -- | BUY | -- |
| 2026-08-05 | Cantor Fitzgerald | -- | BUY | 12.00 |
| 2026-07-31 | Piper Sandler | -- | BUY | 12.00 |
| 2026-07-29 | JonesTrading | -- | BUY | 13.00 |
| 2026-07-16 | Cantor Fitzgerald | -- | BUY | 11.00 |
| 2026-07-15 | JonesTrading | -- | BUY | 13.00 |
| 2026-06-25 | JonesTrading | -- | BUY | 13.00 |
| 2026-06-17 | BMO Capital | -- | BUY | 7.00 |
| 2026-05-22 | Truist Financial | -- | BUY | 12.00 |
| 2026-05-12 | JonesTrading | -- | BUY | 13.00 |
| 2026-05-12 | Truist Financial | -- | BUY | -- |
| 2026-05-12 | Stifel | -- | BUY | 8.00 |
| 2026-05-11 | TD Cowen | -- | BUY | -- |
| 2026-05-11 | BMO Capital | -- | BUY | 7.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Buy
Analyst consensus
Buy
All 2 views agree: bullish.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-05 | After close | ±18.10% | +10.30% (in line) |
| 2026/Q1 | 2026-05-11 | After close | ±12.86% | -5.71% (in line) |
| 2025/Q4 | 2026-02-24 | After close | ±22.38% | -0.93% (in line) |
| 2025/Q3 | 2025-11-06 | After close | ±18.54% | -13.69% (in line) |
| 2025/Q2 | 2025-08-07 | After close | ±26.18% | +0.24% (in line) |
| 2025/Q1 | 2025-05-08 | After close | ±35.07% | +1.00% (in line) |
| 2024/Q4 | 2025-02-27 | After close | ±30.79% | -11.47% (in line) |
| 2024/Q3 | 2024-11-04 | After close | ±19.34% | -5.88% (in line) |
| 2024/Q2 | 2024-08-06 | After close | ±15.79% | -7.72% (in line) |
| 2024/Q1 | 2024-05-07 | After close | ±19.36% | -4.95% (in line) |
| 2023/Q4 | 2024-02-20 | After close | ±19.57% | -9.42% (in line) |
| 2023/Q3 | 2023-11-02 | After close | ±19.28% | +6.09% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 07:00:16 · For reference only, not investment advice and not tailored to your situation.